Glenmark share

Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for U.S. FDA Approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg

Synopsis Glenmark Pharmaceuticals' Q4 consolidated profit before exceptional items and tax was INR3.09bn ($37.78m) for the quarter ended 31 March, down 12.3% compared to a year earlier, due to increased input costs and lower demand in the Indian drugs market. The firm posted one-time costs of INR8bn due to settlements over lawsuits in the US related to antitrust issues and consumer protection. While its sales rose 11.5%, the Indian drugs segment reported a 6.4% sales decline, accounting for 31% of its total, while North American sales grew by 15.3%. For the quarter, the company had reported a one-time expense of 8 billion rupees in settlements of antitrust claims and consumer protection lawsuits in the Glenmark, which caters to the therapeutic areas such as diabetes, cardiovascular and oral contraceptives, reported a 11.5% rise in quarterly net sales.

Glenmark’s business is separated into three entities – • Glenmark Pharmaceuticals for building a global generic, specialty and OTC business in therapy areas of dermatology, respiratory, oncology among others • Glenmark Life Sciences for manufacturing and marketing APIs • Innovation new company (ICHNOS) to focus on discovery and development of novel, first‐in‐class treatments in the therapeutic areas of immunology, oncology and pain encompassing both NBEs as well as NCEs Glenmark reported some traction in India (ex-Covid), Europe and RoW but US performance was subdued (both YoY and QoQ and so were margins • Sales were up 6% YoY to ₹ 3019 crore • EBITDA was at ₹ 463 crore, down 11% YoY with margins at 15.3% • Adjusted PAT was at ₹ 238 crore (up 2% YoY) [Note: Profit adjusted for one-time loss of ₹ 82.5 crore due to recall and Monroe facility remediation] Q4FY23 Quarterly & FY23 Annual Result Announced for Glenmark Pharmaceuticals Ltd. Glenmark Pharmaceuticals announced Q4FY23 & FY23 results: • Q4FY23: • ROW Business grew by 25.1% YoY to Rs 6,856 million • Europe Business grew by 22.3% YoY to Rs 6,078 million • North America Business recorded growth of 15.3% YoY to Rs 8,507 million • India Business recorded a decline of 6.4% YoY to Rs 8,284 million • EBITDA was at Rs 6,050 million, with a margin of 17.9% • Consolidated revenue was at Rs 33,737 million vs Rs 30,191 million recording an increase of 11.7% YoY • EBITDA was Rs 6,050 million in Q4FY23, as compared to Rs 4,634 milli...

• Company has a healthy Interest coverage ratio of 10.9027118170148. • The Company has been maintaining an effective average operating margins of 20.3610695506684% in the last 5 years. • Company’s PEG ratio is 0.712836786734761. • The company has an efficient Cash Conversion Cycle of -51.0703008849577 days. • The company has a good cash flow management; CFO/PAT stands at 1.04023315553617. Quarterly Result (All Figures in Cr.) PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Net Sales 1785.54 1911.93 2208.21 2161.47 1939.05 Total Expenditure 1623.96 1478.11 1825.78 1722.63 1721.38 Operating Profit 161.59 433.82 382.43 438.84 217.67 Other Income 178.98 346.52 316.73 89.73 232.97 Interest 74.01 39.76 52.47 55.72 58.86 Depreciation 41.77 45.03 46.17 46.22 46.73 Exceptional Items 0 0 0 162.5 -658.37 Profit Before Tax 224.79 695.55 600.52 589.13 -313.33 Tax 19.19 202.97 177.37 158.62 -175.86 Profit After Tax 205.6 492.58 423.15 430.5 -137.47 Adjusted EPS (Rs) 7.29 17.46 15 15.26 -4.87 Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.) PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Net Sales 5520.44 6304.87 6712.63 7567.93 8141.58 Total Expenditure 4419.43 4977.39 5408.4 5677.59 6453.36 Operating Profit 1101 1327.48 1304.23 1890.34 1688.22 Other Income 179.99 475.61 606.79 396.24 614.63 Interest 190.9 223.81 256.39 265.9 236.04 Depreciation 95.93 106.28 138.54 150.82 159.7 Exceptional Items 0 345.19 18.55 73.89 430.33 Profit Before Tax 994.17 1818.18 1534....

• Home • Budget 2022 • Market • CaFE Invest • Commodities • IPO NEWS • IPOs • Economy • Tech • Auto • SME • Mobility • Industry • Banking & Finance • Technology • SME/Start-ups • Audio • Jobs • Education • Mutual Funds • Sports • Money • Insurance • Income Tax • Infrastructure • Railways • Aviation • Roadways • India • Lifestyle • Travel & Tourism • Health • Science • From The Print • International • Edits & Columns • Opinion • FE 360 • Politics • Economy • Personal Finance Print • Front Page • FE Insight • Fe@Campus • Brand Wagon • Todays Paper • ePaper • Photos • Videos • Infographics • Horoscope • archive • Digital Currency Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8141.58 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2022.

Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 8141.58 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2022.

• Company has a healthy Interest coverage ratio of 10.9027118170148. • The Company has been maintaining an effective average operating margins of 20.3610695506684% in the last 5 years. • Company’s PEG ratio is 0.712836786734761. • The company has an efficient Cash Conversion Cycle of -51.0703008849577 days. • The company has a good cash flow management; CFO/PAT stands at 1.04023315553617. Quarterly Result (All Figures in Cr.) PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Net Sales 1785.54 1911.93 2208.21 2161.47 1939.05 Total Expenditure 1623.96 1478.11 1825.78 1722.63 1721.38 Operating Profit 161.59 433.82 382.43 438.84 217.67 Other Income 178.98 346.52 316.73 89.73 232.97 Interest 74.01 39.76 52.47 55.72 58.86 Depreciation 41.77 45.03 46.17 46.22 46.73 Exceptional Items 0 0 0 162.5 -658.37 Profit Before Tax 224.79 695.55 600.52 589.13 -313.33 Tax 19.19 202.97 177.37 158.62 -175.86 Profit After Tax 205.6 492.58 423.15 430.5 -137.47 Adjusted EPS (Rs) 7.29 17.46 15 15.26 -4.87 Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.) PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Net Sales 5520.44 6304.87 6712.63 7567.93 8141.58 Total Expenditure 4419.43 4977.39 5408.4 5677.59 6453.36 Operating Profit 1101 1327.48 1304.23 1890.34 1688.22 Other Income 179.99 475.61 606.79 396.24 614.63 Interest 190.9 223.81 256.39 265.9 236.04 Depreciation 95.93 106.28 138.54 150.82 159.7 Exceptional Items 0 345.19 18.55 73.89 430.33 Profit Before Tax 994.17 1818.18 1534....

Synopsis Glenmark Pharmaceuticals' Q4 consolidated profit before exceptional items and tax was INR3.09bn ($37.78m) for the quarter ended 31 March, down 12.3% compared to a year earlier, due to increased input costs and lower demand in the Indian drugs market. The firm posted one-time costs of INR8bn due to settlements over lawsuits in the US related to antitrust issues and consumer protection. While its sales rose 11.5%, the Indian drugs segment reported a 6.4% sales decline, accounting for 31% of its total, while North American sales grew by 15.3%. For the quarter, the company had reported a one-time expense of 8 billion rupees in settlements of antitrust claims and consumer protection lawsuits in the Glenmark, which caters to the therapeutic areas such as diabetes, cardiovascular and oral contraceptives, reported a 11.5% rise in quarterly net sales. • 862.75 03:59 PM | 16 Jun 2023 61.75 (7.71%) 5,200.05 03:59 PM | 16 Jun 2023 273.35 (5.55%) 4,915.05 03:56 PM | 16 Jun 2023 248.25 (5.32%) 114.25 03:59 PM | 16 Jun 2023 5.35 (4.91%) • 381.30 03:59 PM | 16 Jun 2023 -16.00 (-4.03%) 2,832.05 03:58 PM | 16 Jun 2023 -67.25 (-2.32%) 4,641.95 03:58 PM | 16 Jun 2023 -101.45 (-2.14%) 571.25 03:59 PM | 16 Jun 2023 -7.45 (-1.29%)

Glenmark’s business is separated into three entities – • Glenmark Pharmaceuticals for building a global generic, specialty and OTC business in therapy areas of dermatology, respiratory, oncology among others • Glenmark Life Sciences for manufacturing and marketing APIs • Innovation new company (ICHNOS) to focus on discovery and development of novel, first‐in‐class treatments in the therapeutic areas of immunology, oncology and pain encompassing both NBEs as well as NCEs Glenmark reported some traction in India (ex-Covid), Europe and RoW but US performance was subdued (both YoY and QoQ and so were margins • Sales were up 6% YoY to ₹ 3019 crore • EBITDA was at ₹ 463 crore, down 11% YoY with margins at 15.3% • Adjusted PAT was at ₹ 238 crore (up 2% YoY) [Note: Profit adjusted for one-time loss of ₹ 82.5 crore due to recall and Monroe facility remediation] Q4FY23 Quarterly & FY23 Annual Result Announced for Glenmark Pharmaceuticals Ltd. Glenmark Pharmaceuticals announced Q4FY23 & FY23 results: • Q4FY23: • ROW Business grew by 25.1% YoY to Rs 6,856 million • Europe Business grew by 22.3% YoY to Rs 6,078 million • North America Business recorded growth of 15.3% YoY to Rs 8,507 million • India Business recorded a decline of 6.4% YoY to Rs 8,284 million • EBITDA was at Rs 6,050 million, with a margin of 17.9% • Consolidated revenue was at Rs 33,737 million vs Rs 30,191 million recording an increase of 11.7% YoY • EBITDA was Rs 6,050 million in Q4FY23, as compared to Rs 4,634 milli...

Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for U.S. FDA Approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg